Data from the phase III PARADIGM clinical trial of Vectibix (panitumumab) in Japanese patients with previously untreated unresectable wild-type RAS metastatic colorectal cancer were featured during the plenary session of the 2022 ASCO annual meeting.
Positive updated clinical research highlights the therapeutic potential of CLN-081 in patients with epidermal growth factor receptor exon 20 insertion mutation positive non-small cell lung cancer.
Several ongoing trials demonstrate that CPI-613 (devimistat) is a potential treatment for pancreatic cancer, clear cell sarcoma, and biliary tract cancer.
Updated data have emerged from the ELAINE-2 clinical trial of lasofoxifene plus abemaciclib in women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.
In a letter addressed to FDA Commissioner Robert Califf, Republican leaders of the House Committee on Energy and Commerce and two of its subcommittees raised questions about the increasing number of clinical trials conducted in China by companies seeking FDA approval for “me-too” checkpoint inhibitor drugs.
AmerisourceBergen launched Clinical Trial Navigator, a solution suite that supports biopharmaceutical clinical trial recruitment within community-based specialty practices.
The Committee on Energy and Commerce passed a bill May 18 that would authorize the establishment of the Advanced Research Project Agency for Health as an independent agency within HHS.
ASCO and the Association of Community Cancer Centers jointly released recommendations addressing the lack of equity, diversity, and inclusion in cancer clinical trials.
Latest results from the phase III IKEMA clinical trial evaluating the monoclonal antibody Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) demonstrated a median progression free survival of 35.7 months (HR: 0.58; 95% CI: 25.8-44.0; n=179), compared to 19.2 months in patients treated with Kd alone (95% CI: 15.8-25.1; n=123), in patients with relapsed multiple myeloma.
Eighty-seven organizations representing patients with chronic and acute health conditions sent a letter to Congress urging them to improve the diversity of enrollment in clinical trials as part of this year’s Prescription Drug User Fee Act reauthorization.
